Evommune to Present Positive Phase 2a EVO301 Atopic Dermatitis Data as Late-Breaker at EADV 2026

Evommune announced a late-breaking oral presentation of positive Phase 2a data for EVO301 in moderate-to-severe atopic dermatitis at EADV 2026.Key Highlights:Original SEC Filing: Evommune, Inc. [ EVMN ] - 8-K - Sep. 23, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verify…